Nordic Biomarker appoints Jonas Wahlqvist as new CEO

Nordic Biomarker has appointed Jonas Wahlqvist as CEO, effective 1 June. Jonas succeeds Rikard Rodén, who has led the company since 2016 and will remain with Nordic Biomarker during a transition period.

Jonas Wahlqvist joined Nordic Biomarker as Sales and Marketing Director in January 2024 and has over the past two years played a central role in the company’s commercial efforts and in accelerating its international expansion. He brings broad strategic experience from McKinsey & Company, alongside a strong track record of leadership and entrepreneurial roles within digital and technology-enabled businesses.

Johan Conradsson, Chairman of the Board, comments: ”We are delighted to welcome Jonas as the new CEO of Nordic Biomarker. Jonas has made a solid impact during his two years with the company, and together with him we look forward to taking Nordic Biomarker to the next level – with an increasingly global commercial footprint and the opportunities this brings. We would also like to extend our sincere thanks to Rikard for leading the company through an incredible growth journey and helping put Umeå and Linköping on the global map within life science, including achievements such as the Swedish Government’s prize “Exporter of the Year”.

Jonas Wahlqvist, incoming CEO of Nordic Biomarker, comments:

”It is a privilege to take on the role as CEO of Nordic Biomarker. We have a world-class team, a strong product offering and a clear opportunity to grow our position internationally. I look forward to working with the organization, the board and our customers to build on the strong foundation that Rikard and the team have created.”

For further information, please contact:
Jonas Wahlqvist, jonas.wahlqvist@nordicbiomarker.com